The Different Company

China Nicorandil Market Research Report 2022: Sales 2017-2021, Major Manufacturers 2017-2021, Sales Prices 2021-2022, Future Prospects 2022-2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022
Health, Pharmaceutical, Woman, Ageing, Moyamoya disease, Muscle tissue, Sudden death, Face, Growth, Myocardial infarction, Incidence, Prevalence, Angina, ATP, Pollution, Diastole, Coronary artery disease, Man, Patient, Dosage form, COVID-19, Prognosis, Potassium, Hypoxia, CAGR, China Energy Research Report, WHO, Tablet, Hypertension, The Different Company, Research report, Heart, Renewable energy, Animal, Pharmaceutical industry, Lithium, Iron, Generic drug, Nicorandil, Shan Tianfang

The "Research Report on China's Nicorandil Market, 2022-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Nicorandil Market, 2022-2031" report has been added to ResearchAndMarkets.com's offering.
  • The analyst survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year.
  • The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.
  • The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

Research Report on China's Zoledronic Acid Market, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Pharmaceutical, Research report, Calcium, Marketing, The Different Company, China Energy Research Report, Cancer, Zoledronic acid, Dosage form, Blood, Osteoporosis, COVID-19, Growth, CAGR, Animal, Dietary supplement, Pharmaceutical industry, Iron, Novartis

The "Research Report on China's Zoledronic Acid Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Zoledronic Acid Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's market research, 4mg of zoledronic acid injection was marketed by Novartis in China in 2004, while 5mg of zoledronic acid injection for osteoporosis was approved in China in 2009.
  • Subsequently, several companies' generic zoledronic acid drugs were marketed in China, decreasing Novartis' share of zoledronic acid market in China.
  • Prospects of China's Zoledronic Acid Market, 2021-2025
    2 Sales of Zoledronic Acid in China, 2016-2020
    2.3 Sales of Zoledronic Acid in China by Dosage Form, 2016-2020
    3 Analysis of Major Zoledronic Acid Manufacturers in China, 2020
    3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    3.5 Sichuan Hairong Pharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group
    3.6 Jiangsu Hengrui Medicine Company Ltd.
    4 Sales Price of Zoledronic Acid of Different Companies in China, 2020-2021
    4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Tianqingyitai)
    4.4 Sichuan Hairong Pharmaceutical Co., Ltd. of Yangzijiang Pharmaceutical Group (Midi)
    4.5 Jiangsu Hengrui Medicine Company Ltd. (Ailang)
    5 Prospects of China's Zoledronic Acid Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005778/en/

China Anastrozole Market Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Research report, China Energy Research Report, Incidence, Risk, The Different Company, Sanduk Ruit, FDA, Ductal carcinoma, AstraZeneca, Dosage form, Woman, Breast cancer, COVID-19, Growth, CAGR, Animal, Pharmaceutical industry, Iron, Motor vehicle, Anastrozole

The "Research Report on China's Anastrozole Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Anastrozole Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's market research, AstraZeneca still occupied more than 80% of China's anastrozole market share in 2020 in terms of market value, thus having a huge competitive advantage.
  • The publisher expects that with the rising incidence of breast cancer in China, anastrozole still has significant room for growth in the Chinese market.
  • Prospects of China's Anastrozole Market, 2021-2025
    2 Sales of Anastrozole in China, 2016-2020
    2.3 Sales of Anastrozole in China by Dosage Form, 2016-2020
    3 Analysis of Major Anastrozole Manufacturers in China, 2020
    3.3 Jiangsu Haian Pharmaceutical Co., Ltd.
    3.4 Chongqing Huapont Pharmaceutical Co., Ltd.
    3.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
    3.6 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    4 Sales Price of Anastrozole of Different Companies in China, 2020-2021
    4.2 Jiangsu Haian Pharmaceutical Co., Ltd. (AiDa)
    4.3 Chongqing Huapont Pharmaceutical Co., Ltd. (RuiTing)
    4.4 Zhejiang Hisun Pharmaceutical Co., Ltd. (YiShuZhi)
    4.5 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (XiangNa)
    5 Prospects of China's Anastrozole Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005773/en/

China Dabigatran Etexilate Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Pharmaceutical, Research report, Rivaroxaban, Ventricular fibrillation, Category, Marketing, The Different Company, FDA, China Energy Research Report, Anticoagulant, EMA, Dosage form, NMPA, Boehringer Ingelheim, Hip, Patient, Embolism, Stroke, COVID-19, Adult, Animal, Pharmaceutical industry, Fine chemical, Dabigatran, Dabigatran

The "Research Report on China's Dabigatran Etexilate Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Dabigatran Etexilate Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's market research, the sales value of dabigatran etexilate in China declined to approximately CNY329 million (USD50.6 million) in 2020 due to COVID-19.
  • Despite the launch of Chia Tai Tianqing's dabigatran etexilate in 2020, Boehringer Ingelheim International GmbH still held more than 99% share of the dabigatran etexilate market in China in terms of sales value.
  • Prospects of China's Dabigatran Etexilate Market, 2021-2025
    2 Sales of Dabigatran Etexilate in China, 2016-2020
    2.3 Sales of Dabigatran Etexilate in China by Dosage Form, 2016-2020
    3 Analysis of Major Dabigatran Etexilate Manufacturers in China, 2020
    3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    4 Sales Price of Dabigatran Etexilate of Different Companies in China, 2020-2021
    4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Anershun)
    5 Prospects of China's Dabigatran Etexilate Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005768/en/

Research Report on China's Levetiracetam Market, 2016-220 & 2021-2025: A First-Line Drug in the Field of Epilepsy Treatment, First Developed by UCB Under the Trade Name of Keppra - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Pharmaceutical, Research report, Work, Life, Marketing, The Different Company, FDA, China Energy Research Report, Dosage form, Shenzhen Kaifa Technology Co., Ltd., UCB, Patient, Population, COVID-19, CAGR, Epilepsy, Patent, Animal, Pharmaceutical industry, Generic drug, Levetiracetam, Levetiracetam

The "Research Report on China's Levetiracetam Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Levetiracetam Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Levetiracetam was first developed by UCB under the trade name of Keppra.
  • In 2009, after the expiration of the patent, generic drugs by Chinese companies were marketed, but Keppra still occupied a major market share.
  • According to the publisher's market research, the sales value of levetiracetam in the Chinese market continued to rise from 2016 to 2019.

China Nicorandil Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Other Manufacturing, Manufacturing, Research report, Diastole, Tablet, The Different Company, ATP, China Energy Research Report, Prognosis, Angina, Dosage form, Moyamoya disease, Face, Heart, Patient, Coronary artery disease, COVID-19, Growth, Potassium, CAGR, Animal, Pharmaceutical industry, Iron, Generic drug, Shan Tianfang, Nicorandil

The "Research Report on China's Nicorandil Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Nicorandil Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The rising number of patients with coronary heart disease in China has contributed to the growth of the market.
  • The publisher's survey data show that from 2016 to 2020, the sales value of nicorandil in the Chinese market kept increasing year by year.
  • The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

China Exemestane Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Women, Consumer, Health, Pharmaceutical, Oncology, Research report, China Energy Research Report, Incidence, Exercise, The Different Company, Cancer, Overweight, Marriage, Dosage form, Lung cancer, Risk, Woman, Obesity, Breast cancer, COVID-19, Growth, CAGR, Animal, Dietary supplement, Pharmaceutical industry, Generic drug, Exemestane

The "Research Report on China's Exemestane Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Exemestane Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • According to the publisher's market research, Pharmacia & Upjoin's exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002.
  • Pharmacia &Upjoin's exemestane (trade name AROMASIN) is extremely competitive in the Chinese market, accounting for more than 90% of China's exemestane market in 2020 in terms of sales value.
  • Prospects of China's Exemestane Market, 2021-2025
    2 Sales of Exemestane in China, 2016-2020
    2.3 Sales of Exemestane in China by Dosage Form, 2016-2020
    3 Analysis of Major Exemestane Manufacturers in China, 2020
    3.4 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd.
    3.5 Tongfang Pharmaceutical Group Co., Ltd.
    4 Sales Price of Exemestane of Different Companies in China, 2020-2021
    4.3 Hainan Tongyong Tongmeng Pharmaceutical Co., Ltd. (YiSiTan)
    4.4 Tongfang Pharmaceutical Group Co., Ltd. (YouKeYi)
    5 Prospects of China's Exemestane Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005741/en/

China Escitalopram Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Health, Pharmaceutical, Research report, China Energy Research Report, Life, Escitalopram, The Different Company, Urbanization, Dosage form, Depression, Patient, COVID-19, Steven N. S. Cheung, CAGR, Animal, Pharmaceutical industry, Motor vehicle, Generic drug

The "Research Report on China's Escitalopram Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Escitalopram Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Companies with a relatively large market share of escitalopram in China include Sichuan Kelun Pharmaceutical, Jewim Pharmaceutical, Hunan Dongting Pharmaceutical and Jinhua CONBA.
  • From 2021 to 2025, it is likely to see a recovery increase in the market size of escitalopram in China.
  • Prospects of China's Escitalopram Market, 2021-2025
    2 Sales of Escitalopram in China, 2016-2020
    2.3 Sales of Escitalopram in China by Dosage Form, 2016-2020
    3 Analysis of Major Escitalopram Manufacturers in China, 2020
    3.3 Sichuan Kelun Pharmaceutical Co., Ltd.
    3.4 Jewim Pharmaceutical (Shandong) Co., Ltd.
    3.5 Hunan Dongting Pharmaceutical Co., Ltd.
    3.6 Zhejiang Jinhua CONBA Bio-pharm.

Research Report on China's Alectinib Markets, 2016-2020 & 2021-2025: Originally Developed by Roche for Patients with the Zotinib-Resistant ALK-Positive Non-Small Cell Lung Cancer - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Roche, Research report, CSCO, EML4-ALK positive lung cancer, Category, Risk, Marketing, ESMO, The Different Company, Insurance, FDA, China Energy Research Report, Pollution, Dosage form, Lung cancer, NCCN, Nominal interest rate, HIV disease progression rates, Occupational Safety and Health Act 1994, Patient, COVID-19, Death, Capsule, CAGR, Income, NSCLC, Animal, Pharmaceutical industry, Health insurance, Alectinib

The "Research Report on China's Alectinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Alectinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Alectinib, originally developed by Roche, was first approved by the FDA on December 11, 2015, for patients with the zotinib-resistant ALK-positive non-small cell lung cancer.
  • On November 6, 2017, the FDA also approved alectinib as a first-line agent for ALK-positive patients.
  • However, for most Chinese patients, the monthly expenditure of approximately CNY15,230 (USD2,340) on alectinib is still too high.

Research Report on China's Gefitinib Markets, 2016-2020 & 2021-2025: The World's First Marketed EGFR-TKI, Originally Developed by AstraZeneca - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022
Pharmaceutical, Health, Oncology, Research report, CSCO, Category, Tablet, Marketing, The Different Company, China Energy Research Report, AstraZeneca, Pollution, Dosage form, Lung cancer, Guideline, Yangtze River Pharmaceutical Group, Jiangsu Hengrui Medicine, American Society of Clinical Oncology, EGFR, Patient, COVID-19, Pharmacy Council of India, CAGR, Income, Animal, Pharmaceutical industry, Gefitinib

The "Research Report on China's Gefitinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Gefitinib Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • AstraZeneca's gefitinib, with the trade name of Iressa, was approved in the United States in 2003 and in China in 2004.
  • Before the launch of domestic generic drugs in China, the only gefitinib available in the market was the original drug Iressa, with a high price.
  • According to the publisher's market research, before 2019, the sales value of China's gefitinib market kept growing year by year.